PositoAI
a positivity index
Home Explore Actions Flows Indices News Watchlist Compare PosiDemy Screeners Insights
PosiFunda · Fundamentals

XWELL, Inc.

PosiFunda Ratios Only on PositoAI

PositoAI's own ratios from XWELL, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.

What stands out

  • Cash Cushion Ratio: Debt, after subtracting cash, is 1.4 times its market value (net debt). Lower than 96% of Healthcare companies in United States.
  • Cash Locked Ratio: Money owed to suppliers is larger than money owed by customers plus stock: $6 per $100 of sales comes from others' credit, against $2 tied up three years earlier. Less money tied up than 94% of Healthcare companies in United States.
  • Tangible Assets Ratio: Of every $100 the company owns, $99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 89% of Healthcare companies in United States.

Where $100 of sales goes

$132Operating costs$0.5Interest$58Net loss

Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.

Cash quality

Profit Cash Ratio

—

Loss-making or profit too small

Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.

Self-Funding Ratio

-5.0×

Over the last 3 years operating cash was negative while the company kept spending on investment (capex).

Higher than 55% of Healthcare companies in United States.

Cash Locked Ratio

−$6

Money owed to suppliers is larger than money owed by customers plus stock: $6 per $100 of sales comes from others' credit, against $2 tied up three years earlier.

Less money tied up than 94% of Healthcare companies in United States.

Growth quality

Steadiness Ratio

1/3 · 2/3

Sales grew in 1 of the last 3 years; profit grew in 2 of 3.

Steadier than 50% of Healthcare companies in United States.

Growth Efficiency Ratio

—

Sales fell 48%

Sales fell 48% in 3 years, so extra profit per extra sales cannot be measured.

Asset Productivity Ratio

-48% / -84%

In 3 years sales changed by -48% while total assets changed by -84%. Sales grew faster than assets.

Balance-sheet strength

Debt Due Cover Ratio

-2.4×

Operating cash was negative last year, while some debt falls due within a year.

Higher than 63% of Healthcare companies in United States.

Cash Cushion Ratio

1.4× debt

Debt, after subtracting cash, is 1.4 times its market value (net debt).

Lower than 96% of Healthcare companies in United States.

Tangible Assets Ratio

99%

Of every $100 the company owns, $99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.

More tangible than 89% of Healthcare companies in United States.

Tangible Net Worth Ratio

—

Data incomplete

Shareholders

Shareholder Slice Ratio

+46%

Share count rose 46% in 3 years, so each share's slice of the company became smaller.

Bigger rise in share count than 55% of Healthcare companies in United States.

Standard fundamentals

P/E, P/B, ROE, debt, growth and more (12)

XWELL, Inc. made a loss over the last year. XWELL, Inc. owes $0.60 for every $1 it owns. XWELL, Inc. made a loss in each of the last two years.

Compared with Healthcare companies in United States · latest annual results Dec 2025.

P/E ratio

Loss

XWELL, Inc. made a loss over the last year, so its P/E ratio is not meaningful.

P/B ratio

-3.68

XWELL, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.

Market cap

$7 M

The total market value of all of XWELL, Inc.'s shares at today's price (share price × number of shares), smaller than 91% of Healthcare companies in United States. PosiCap size class: Nano Cap.

Net worth (book value)

Negative

XWELL, Inc.'s net worth is negative ($2 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.

Return on equity (ROE)

-361.4%

XWELL, Inc. lost 361.4% of its shareholders' money over the last year, lower than 91% of Healthcare companies in United States.

Owes vs Owns

0.60×

XWELL, Inc. owes $0.60 for every $1 it owns (moderate), higher than 65% of Healthcare companies in United States.

Dividend yield

None

XWELL, Inc. does not currently pay a dividend.

Revenue growth

-14%

Revenue fell 14% in the year to Dec 2025, and shrank 19% a year on average over 3 years.

Profit growth

Loss

XWELL, Inc. made a loss in each of the last two years.

Profit margin

-58.2%

XWELL, Inc. lost $58 for every $100 of revenue.

Interest cover

Not covered

XWELL, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.

Cash vs debt

Net debt

XWELL, Inc. had $10 M more debt than cash (net debt) at Dec 2025.

Questions

What is XWELL, Inc.'s return on equity?

XWELL, Inc. lost 361.4% of its shareholders' money over the last year, lower than 91% of Healthcare companies in United States.

How much does XWELL, Inc. owe compared with what it owns?

XWELL, Inc. owes $0.60 for every $1 it owns (moderate), higher than 65% of Healthcare companies in United States.

Does XWELL, Inc. pay a dividend?

No. XWELL, Inc. does not currently pay a dividend.

Is XWELL, Inc.'s revenue growing?

Revenue fell 14% in the year to Dec 2025, and shrank 19% a year on average over 3 years.

Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.

Disclaimer — PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.